Coiled Therapeutics Strengthens AO-252 Programme with Leading Cancer Scientist

Why It Matters

Securing a world‑renowned TACC3 expert validates AO‑252’s mechanism and may fast‑track its clinical development, offering investors a differentiated precision‑oncology asset with early efficacy signals.

Key Takeaways

• Coiled adds Prof. Ozgur Sahin to AO‑252 advisory board.
• AO‑252 is a selective TACC3 protein‑protein interaction inhibitor.
• Early trials show ~30% tumor regression without safety concerns.
• Drug may enhance DNA repair inhibition and immune response in cancers.
• Sahin’s endorsement signals strong scientific validation for precision oncology.

Summary

Coiled Therapeutics announced the addition of leading cancer scientist Prof. Ozgur Sahin to its scientific advisory board for AO‑252, a TACC3‑targeting agent.

AO‑252 is a selective protein‑protein interaction inhibitor of TACC3, designed to disrupt interactions crucial for tumor growth, DNA damage repair, and immune modulation. Early clinical data show approximately 30% tumor regression, no dose‑limiting toxicities, and dose escalation not yet reaching the maximum tolerated dose.

Executive Chairman Dr. Sotirios Stergiopoulos highlighted Sahin’s role in defining TACC3 biology and praised the drug as “one of the most exciting opportunities” in precision oncology. Sahin’s prior work in Turkey and collaboration with Coiled underpin the scientific credibility.

The endorsement and advisory role could accelerate investor confidence, broaden indication selection, and position AO‑252 as a potential game‑changer in oncology pipelines, especially for tumors reliant on TACC3 pathways.

Original Description

Coiled Therapeutics (AIM:COIL, OTCQB:COTXF) executive chairman Dr Sotirios Stergiopoulos joined Proactive's Stephen Gunnion to discuss the appointment of Professor Ozgur Sahin as a Scientific Advisor to the company and the progress of lead cancer therapy AO-252.

Stergiopoulos explained why Sahin, a leading expert in TACC3 biology, is a key addition as the company advances the programme. He also highlighted encouraging early clinical data, including signs of tumour regression with no safety concerns reported to date, and outlined plans to begin dosing patients with a new AO-252 formulation in July.

For more interviews and market insights, visit the Proactive YouTube channel. Don't forget to like this video, subscribe to the channel and enable notifications so you never miss future content.

#CoiledTherapeutics #AO252 #PrecisionOncology #CancerResearch #Biotech #Oncology #ClinicalTrials #TACC3 #DrugDevelopment #HealthcareInnovation #CancerTreatment #MedicalResearch #Biotechnology #LifeSciences #ProactiveInvestors